EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Complement component C3 as a new target to lower albuminuria in hypertensive kidney disease

Marlies Bode, Jan Niklas Diemer, The Vinh Luu, Nikolas Ehnert, Teresa Teigeler, Thorsten Wiech, Maja T Lindenmeyer, Georg R Herrnstadt, Jasmin Bülow, Tobias B Huber, Nicola M Tomas, Ulrich O Wenzel iD

British Journal of Pharmacology · 2023

DOI: 10.1111/bph.16097 ↗

At a glance

Journal article in British Journal of Pharmacology, 2023. Written by Marlies Bode and 11 co-authors. Institution: III. Department of Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany. Major MEDLINE topics: Hypertension, Hypertension, Renal. Cited 10 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: Deutsche Forschungsgemeinschaft.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Complement activation may drive hypertension through its effects on immunity and tissue integrity. Experimental Approach We examined expression of C3, the central protein of the complement cascade, in hypertension. Key Results Increased C3 expression was found in kidney biopsies and micro‐dissected glomeruli of patients with hypertensive nephropathy. Renal single cell RNA sequence data from normotensive and hypertensive patients confirmed expression of C3 in different cellular compartments of the kidney. In angiotensin II (Ang II) induced hypertension renal C3 expression was up‐regulated. C3 −/− mice revealed a significant lower albuminuria in the early phase of hypertension. However, no difference was found for blood pressure, renal injury (histology, glomerular filtration rate, inflammation) and cardiac injury (fibrosis, weight, gene expression) between C3 −/− and wildtype mice after Ang II infusion. Also, in deoxycorticosterone acetate (DOCA) salt hypertension, a significantly lower albuminuria was found in the first weeks of hypertension in C3 deficient mice but no significant difference in renal and cardiac injury. Down‐regulation of C3 by C3 targeting GalNAc ( n ‐acetylgalactosamine) small interfering RNA (siRNA) conjugate decreased C3 in the liver by 96% and lowered albuminuria in the early phase but showed no effect on blood pressure and end‐organ damage. Inhibition of complement C5 by siRNA showed no effect on albuminuria. Conclusion and Implications Increased C3 expression is found in the kidneys of hypertensive mice and men. Genetic and therapeutic knockdown of C3 improved albuminuria in the early phase of hypertension but did not ameliorate arterial blood pressure nor renal and cardiac injury.

Subjects

MeSH terms (MEDLINE)

HypertensionHypertension, RenalBlood PressureAlbuminuriaNephritisKidneyRNA, Small InterferingMiceAnimalsAngiotensin II

Author keywords

C3DOCA saltalbuminuriaangiotensin IIcardiac damagerenal damage

Substances

Angiotensin IIRNA, Small Interfering

Authors and institutions

  • III. Department of Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Institute for Pathology, Section Nephropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Institute of Orthopedic Research and Biomechanics, University Medical Center Ulm, Ulm, Germany.

ORCID profiles: Ulrich O Wenzel

Funding

  • Deutsche Forschungsgemeinschaft

Cite

APA

Bode, M., Diemer, J. N., Luu, T. V., Ehnert, N., Teigeler, T., Wiech, T., Lindenmeyer, M. T., Herrnstadt, G. R., Bülow, J., Huber, T. B., Tomas, N. M., & Wenzel, U. O. (2023). Complement component C3 as a new target to lower albuminuria in hypertensive kidney disease. British Journal of Pharmacology. https://doi.org/10.1111/bph.16097

Vancouver

Bode M, Diemer JN, Luu TV, Ehnert N, Teigeler T, Wiech T, et al. Complement component C3 as a new target to lower albuminuria in hypertensive kidney disease. British Journal of Pharmacology. 2023. doi:10.1111/bph.16097

BibTeX
@article{Bode2023,
  author = {Bode, Marlies and Diemer, Jan Niklas and Luu, The Vinh and Ehnert, Nikolas and Teigeler, Teresa and Wiech, Thorsten and Lindenmeyer, Maja T and Herrnstadt, Georg R and Bülow, Jasmin and Huber, Tobias B and Tomas, Nicola M and Wenzel, Ulrich O},
  title = {Complement component C3 as a new target to lower albuminuria in hypertensive kidney disease},
  journal = {British Journal of Pharmacology},
  year = {2023},
  doi = {10.1111/bph.16097}
}
Start for free →